By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT 1st Quarter 2025 Financial & Operating Results On May 14, 2025, CytoSorbents (NASDAQ:CTSO) reported 1 st quarter 2025 financial ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has ...

On March 31, 2025, CytoSorbents reported 4th quarter and full year 2024 results. In the 4 th quarter, product revenue was $9.2 million, which was an increase of 25% compared to $7.3 million in the ...

Positive Points CytoSorbents Corp (NASDAQ:CTSO) reported a solid gross margin performance of 71%, consistent with the 2024 average, indicating effective pricing and cost controls. The company is ...

March 31, 2025 — 04:55 pm EDT Written by Quiver EarningsTracker for Quiver Quantitative -> ...

On May 14, 2025, CytoSorbents (NASDAQ:CTSO) reported 1 st quarter 2025 financial and operating results. In the 1 st quarter, product revenue was $8.7 million, which was flat on a constant currency ...